Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 2 January 1987:
Vol. 235. no. 4784, pp. 85 - 88
DOI: 10.1126/science.3541203
Prev | Table of Contents | Next

Articles

Science, Vol 235, Issue 4784, 85-88
Copyright © 1987 by American Association for the Advancement of Science

articles

Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL

SS Clark, J McLaughlin, WM Crist, R Champlin, and ON Witte

In the Philadelphia chromosome (Ph1) of chronic myelogenous leukemia (CML), the c-abl gene on chromosome 9 is translocated to bcr on chromosome 22. This results in the expression of a chimeric bcr-abl message that encodes the P210bcr-abl tyrosine kinase. The cells of 10% of acute lymphocytic leukemia patients (ALL) carry a cytogenetically similar Ph1 translocation. We report that Ph1-positive ALL cells express unique abl-derived tyrosine kinases of 185 and 180 kilodaltons that are distinct from the bcr-abl-derived P210 protein of CML. The appearance of the 185/180-kilodalton proteins correlates with the expression of a novel 6.5-kilobase messenger RNA. Thus, similar genetic translocations in two different leukemias result in the expression of distinct c-abl-derived products.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
IKZF1 (Ikaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report.
G. Martinelli, I. Iacobucci, C. T. Storlazzi, M. Vignetti, F. Paoloni, D. Cilloni, S. Soverini, A. Vitale, S. Chiaretti, G. Cimino, et al. (2009)
J. Clin. Oncol. 27, 5202-5207
   Abstract »    Full Text »    PDF »
RNAi screen for rapid therapeutic target identification in leukemia patients.
J. W. Tyner, M. W. Deininger, M. M. Loriaux, B. H. Chang, J. R. Gotlib, S. G. Willis, H. Erickson, T. Kovacsovics, T. O'Hare, M. C. Heinrich, et al. (2009)
PNAS 106, 8695-8700
   Abstract »    Full Text »    PDF »
The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias.
R.T. Williams and C.J. Sherr (2008)
Cold Spring Harb Symp Quant Biol
   Abstract »    PDF »
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
C. G. Mullighan, R. T. Williams, J. R. Downing, and C. J. Sherr (2008)
Genes & Dev. 22, 1411-1415
   Abstract »    Full Text »    PDF »
Regulation of Cellular Transformation by Oncogenic and Normal Abl Kinases.
J. Suzuki and T. Shishido (2007)
J. Biochem. 141, 453-458
   Abstract »    Full Text »    PDF »
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
R. T. Williams, M. F. Roussel, and C. J. Sherr (2006)
PNAS 103, 6688-6693
   Abstract »    Full Text »    PDF »
Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion.
S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang (2003)
Clin. Cancer Res. 9, 4494-4504
   Abstract »    Full Text »    PDF »
Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl+ K562 leukemic cells by Gab2.
J. F. Dorsey, J. M. Cunnick, S. M. Mane, and J. Wu (2002)
Blood 99, 1388-1397
   Abstract »    Full Text »    PDF »
The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis.
E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock (2001)
Cancer Res. 61, 2343-2355
   Full Text »
The Pyrido[2,3-d]pyrimidine Derivative PD180970 Inhibits p210Bcr-Abl Tyrosine Kinase and Induces Apoptosis of K562 Leukemic Cells.
J. F. Dorsey, R. Jove, A. J. Kraker, and J. Wu (2000)
Cancer Res. 60, 3127-3131
   Abstract »    Full Text »
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
C. Cobaleda and I. Sanchez-Garcia (2000)
Blood 95, 731-737
   Abstract »    Full Text »    PDF »
Signaling Pathways Activated by Oncogenic Forms of Abl Tyrosine Kinase.
X. Zou and K. Calame (1999)
J. Biol. Chem. 274, 18141-18144
   Full Text »    PDF »
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation.
T. Guillaume, D. B. Rubinstein, and M. Symann (1998)
Blood 92, 1471-1490
   Full Text »    PDF »
Development of Acute Lymphoblastic Leukemia and Myeloproliferative Disorder in Transgenic Mice Expressing p210bcr/abl: A Novel Transgenic Model for Human Ph1-Positive Leukemias.
H. Honda, H. Oda, T. Suzuki, T. Takahashi, O. N. Witte, K. Ozawa, T. Ishikawa, Y. Yazaki, and H. Hirai (1998)
Blood 91, 2067-2075
   Abstract »    Full Text »    PDF »
A BCR-ABLp190 Fusion Gene Made by Homologous Recombination Causes B-Cell Acute Lymphoblastic Leukemias in Chimeric Mice With Independence of the Endogenous bcr Product.
A. Castellanos, B. Pintado, E. Weruaga, R. Arevalo, A. Lopez, A. Orfao, and I. Sanchez-Garcia (1997)
Blood 90, 2168-2174
   Abstract »    Full Text »    PDF »
Molecular Genetic Advances in Chronic Myelogenous Leukemia.
D. E. Epner and H. P. Koeffler (1990)
Ann Intern Med 113, 3-6
   Abstract »    PDF »
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
T. Lugo, A. Pendergast, A. Muller, and O. Witte (1990)
Science 247, 1079-1082
   Abstract »    PDF »
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
S. Clark, J McLaughlin, M Timmons, A. Pendergast, Y Ben-Neriah, L. Dow, W Crist, G Rovera, S. Smith, and O. Witte (1988)
Science 239, 775-777
   Abstract »    PDF »
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.
G. Daley, J McLaughlin, O. Witte, and D Baltimore (1987)
Science 237, 532-535
   Abstract »    PDF »
Disease diagnosis by recombinant DNA methods.
C. Caskey (1987)
Science 236, 1223-1229
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)